Penny stocks are some of the most affordable investments on the market, valued at less than $5. They can hold a unique and intriguing position that can be highly profitable. However, despite their low prices, these stocks are often the riskiest to own. Many are still in the process of establishing themselves in their respective markets or lack a solid foundation for significant growth. That said, there are exceptions. These three penny stocks are loaded with growth potential and have exciting developments c ...

Privacy watchdogs in the U.K. and Canada have launched a joint investigation into the data breach at 23andMe last year. On Monday, the U.K,’s Information Commissioner’s Office (ICO) and the Office of the Privacy Commissioner of Canada (OPC) announced their investigation into the genetic testing company, saying the organizations will leverage “the combined resources and expertise of their two offices.”  Last year, 23andMe disclosed a security incident that affected the genetic and ancestry data of 6.9 milli ...

SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at higher likelihood for being diagnosed with the condition. Bipolar disorder is a mental health condition that can cause extreme and unusual shifts in mood, energy, behavior and activity, ranging from highs (mania) to l ...

Is altruism a good idea for an unprofitable capitalistic enterprise?Genetic database builder 23andMe (ME -11.45%) stock slid 10% through 12:05 p.m. ET Tuesday. Curiously, though, the news that 23andMe reported today seemed generally of the "good" variety. The company announced a collaboration with the nonprofit Colorectal Cancer Alliance "to help advance research on colorectal cancer in the Black/African American community." Now, why might investors consider this bad news for 23andMe stock?Non-profit plus a ...

SUNNYVALE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading genetic health and biopharmaceutical company, and the Colorectal Cancer Alliance (Alliance), the largest nonprofit organization dedicated to ending colorectal cancer, announced a collaboration to help advance research on colorectal cancer in the Black/African American community. The Genetic Insights into Colorectal Cancer in the Black Community Study is part of 23andMe's continued efforts to raise aware ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ______________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM___________ TO___________ Commission File Number 001-39587 ___________________________________________ ...

The LRRK2 variant is strongly associated with symptoms of Parkinson's disease (PD) that are different from non-variant carriers with the disease The study revealed novel findings of genetic "hotspots" in people from Mexico, Cuba, Puerto Rico, and Brazil, where the founder variant has sprung up in other communities 23andMe has the largest LRRK2 G2019S research cohort, and launched the Parkinson's Impact Project (PIP) in 2018 to better understand which carriers are at greater risk of developing Parkinson's di ...

分组1 - 公司正在进行战略评估,包括可能的私有化交易 [8][9][10][11] - 公司将重点关注高回报的现金用途,包括会员服务、远程医疗和利用数据资产创造可持续的盈利研究业务 [13][14][15] - 消费者业务方面,公司已经超过1500万客户里程碑,并持续创新会员服务以提高客户价值 [16][17][18][19][20][21][22] - 远程医疗业务正在实现盈利,并推出新产品以提高客户终身价值 [23][24] 分组2 - 研究业务正在转型,与GSK的合作已转为非独家,公司正与更多潜在合作伙伴接洽 [25][26][27][28] - 公司正在利用人工智能技术,包括大语言模型,来增强消费者和合作伙伴业务 [27][28] - 治疗业务取得进展,两个候选药物已进入临床试验阶段 [29][30] 问答环节重要的提问和回答 问题1 **David Lebowitz 提问** 询问公司即将发布的2期临床试验数据的预期 [52] **Jennifer Low 回答** 公司将在ASCO会议上发布2期试验的初步疗效、安全性和生物标志物数据 [54][55] 问题2 **Steven Mah 提问** 询问公司如何管理现金流,特别是在推进高价值治疗项目的同时 [69] **Joe Selsavage 回答** 公司将继续控制开支,同时确保为ME-610和1473项目的临床试验提供资金支持 [70] 问题3 **投资者提问** 询问公司是否有计划与制药公司进一步合作,利用公司的数据资产 [73] **Anne Wojcicki 回答** 公司将继续寻求与制药行业的合作,利用数据加速药物发现和开发 [74][75]

EXHIBIT 99.1 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results SOUTH SAN FRANCISCO, Calif., May 23, 2024 -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024 (FY24), which ended March 31, 2024. Key Results and Recent Developments • On March 28, 2024 the Board of Directors of 23andMe formed a Special Committee comprised of independent directors to review str ...

SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024 (FY24), which ended March 31, 2024. Key Results and Recent Developments On March 28, 2024 the Board of Directors of 23andMe formed a Special Committee comprised of independent directors to review strategic alternatives that may be available to 23andMe to maximize sharehol ...